Abstract
Health technology assessments (HTAs) inform reimbursement decisions. International differences in HTA processes lead to international differences in patient access to new treatments. Using HTAs for nivolumab plus chemotherapy in first-line gastric cancer as an example, we quantified the variation in time to patient access and in the evaluation of benefits between different HTA agencies.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call